Sodium–glucose cotransporter (SGLT) 2 inhibitors were originally developed to lower glucose levels for the treatment of individuals with type 2 diabetes (T2D) in an insulin-independent manner by inhibiting glucose reabsorption from the proximal renal tubules. This evidence concerns the gene INS and type 2 diabetes mellitus.